Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Colorcon
Moodys
AstraZeneca
Express Scripts

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,248,172

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,248,172
Title:Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
Abstract: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an .alpha.-2-macroglobulin (.alpha.2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an .alpha.2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or .alpha.2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.
Inventor(s): Srivastava; Pramod K. (Avon, CT), Li; Zihai (Mount Pleasant, SC)
Assignee: University of Connecticut Health Center (Farmington, CT)
Application Number:14/043,666
Patent Claims:1. A method of treating a cancer in a subject in need thereof, the method comprising: administering to the subject Bevacizumab, wherein the subject is a candidate for receiving Bevacizumab to treat the cancer, and wherein the subject has been administered a purified heat shock protein preparation comprising a heat shock protein-peptide complex comprising a heat shock protein covalently or noncovalently attached to an antigenic peptide, wherein the antigenic peptide displays antigenicity of an antigen of the cancer.

2. The method of claim 1, wherein the purified heat shock protein preparation comprises heat shock protein-peptide complexes that comprise one or more of hsp70, hsp90, hsp110, gp96, grp170, and calreticulin.

3. The method of claim 2, wherein the purified heat shock protein preparation comprises heat shock protein-peptide complexes that comprise gp96.

4. The method of claim 1, wherein the subject receives further administrations of Bevacizumab and the purified heat shock protein preparation, wherein the administrations are repeated for up to 12 cycles.

5. The method of claim 1, wherein the subject is administered the purified heat shock protein preparation once a week for the first 4 weeks after an initial administration of the purified heat shock protein preparation.

6. The method of claim 5, wherein the subject is administered the purified heat shock protein preparation once every other week after the first 4 weeks of administration of the purified heat shock protein preparation.

7. The method of claim 1 further comprising administering to the subject radiation therapy.

8. The method of claim 1, wherein the Bevacizumab is administered for a first period of time, followed by a further administration of the purified heat shock protein preparation for a second period of time, wherein this sequential administration is repeated.

9. The method of claim 1, wherein Bevacizumab is administered concurrently with further administrations of the purified heat shock protein preparation.

10. The method of claim 1, wherein the Bevacizumab is cyclically administered with purified heat shock protein preparation.

11. The method of claim 1, wherein the purified heat shock protein preparation is autologous to the subject.

12. The method of claim 1, wherein the subject is human.

13. The method of claim 12, wherein the purified heat shock protein preparation comprises heat shock protein-peptide complexes isolated from cells of the cancer.

14. The method of claim 1, wherein the purified heat shock protein preparation comprises heat shock protein-peptide complexes comprising heat shock proteins non-covalently attached to antigenic peptides.

15. The method of claim 1, wherein the antigenic peptide displays antigenicity of a tumor-specific antigen or a tumor-associated antigen of the cancer.

16. The method of claim 1, wherein the cancer is a relapse form of cancer.

17. The method of claim 16, wherein the subject is human and wherein the antigenic peptide displays antigenicity of a tumor-specific antigen or a tumor-associated antigen of the cancer.

18. The method of claim 1, wherein the Bevacizumab is administered intravenously.

19. The method of claim 18, wherein the purified heat shock protein preparation is administered intradermally.

20. The method of claim 1, wherein the purified heat shock protein preparation is administered intradermally.

Details for Patent 9,248,172

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial University of Connecticut Health Center (Farmington, CT) 2022-04-25 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial University of Connecticut Health Center (Farmington, CT) 2022-04-25 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Baxter
Moodys
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.